Activity Overview
This online, on-demand virtual symposium brings together experts in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), an increasingly recognized inflammatory demyelinating disorder with distinct clinical, radiographic, and immunologic features. In this educational program, these experts share data and expert commentary drawn from years of treating patients with MOGAD. Faculty will focus on when to suspect MOGAD, how to interpret clinical presentations across age groups, and the optimal use and limitations of serum MOG-IgG testing, including assay selection and result interpretation. This educational activity is an archive of the live virtual symposium held on February 6, 2026.
Target Audience
This educational activity is directed toward neurologists, specialty neurologists, nurses, specialty nurse practitioners, and specialty physician assistants involved in the care of patients with neurological disease.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Describe the burden of disease of MOGAD
- Identify the differential diagnosis for MOGAD
- Implement diagnostic criteria to differentiate MOGAD from other similar disorders
Michael Levy, MD, PhD
Associate Professor
Department of Neurology
Harvard Medical School and Massachusetts General Hospital
Boston, MA
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Alexion/AstraZeneca, Genentech/Roche, Horizon/Amgen, UCB; Grant/Research Funding: Alexion/AstraZeneca, Genentech/Roche, Horizon/Amgen, UCB, Sanofi
Jeffrey L. Bennett, MD, PhD
Gertrude Gilden Professor
Vice Chair, Basic Research - Neurology
Departments of Neurology and Ophthalmology
Programs in Neuroscience and Immunology
University of Colorado Anschutz School of Medicine
Aurora, CO
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Alexion, Amgen, Chugai, CorEvitas, Genentech, ImmPACT Bio, Mitsubishi Tanabe, Novartis, Roche, UCB Pharma; Grant/Research Funding: Alexion, DOD, Genentech, National Institute of Neurological Disorders and Stroke; Royalty or Patent Benefits: Compositions and Methods for the Treatment of Neuromyelitis Optica; Other: Roche
Eoin P. Flanagan, MB, BCh
Marilyn A. Park and Moon S. Park Director, Center for Multiple
Sclerosis
and Autoimmune Neurology
Chair, Division of Multiple Sclerosis and Autoimmune Neurology
Professor of Neurology,
Department of Neurology
Mayo Clinic
Rochester, MN
Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Alexion/AstraZeneca, Genentech/Roche, Horizon/Amgen, UCB; Grant/Research Funding: Alexion/AstraZeneca, Genentech/Roche, Horizon/Amgen, Sanofi, UCB; Advisor, Consultant, Speaker, Honoraria Recipient: Alexion, Genentech, Horizon Therapeutics, UCB; Grant/Research Funding: Merck, Roche, UCB; Royalty or Patent Benefits: UpToDate; Other (Medical Advisory Board): MOG project, Sumaira Foundation; Other (Editorial Board Member): The Journal of the Neurological Sciences; Neuroimmunology Reports; Neurology Neuroimmunology & Neuroinflammation
The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible companies.
PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Off-Label Disclosure and Disclaimer
This accredited activity has been developed in accordance with applicable accreditation standards to ensure balance, independence, objectivity, and scientific rigor. Faculty were instructed to use generic names where possible and to base recommendations on the best available evidence.
In the context of clinical discussion, proprietary product names may be mentioned. Such references are made for educational purposes only and do not constitute endorsement of any commercial product or service.
Learners are encouraged to independently evaluate the information presented and apply their own clinical judgment when considering patient care decisions.
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.